Press release Innovation Credit_InteRNA
November 16, 2010
Date: 16 November, 2010 InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company developing path...
KWF Kankerbestrijding reikt KWO-prijzen 2010 uit.
October 12, 2010
6 mln euro voor tumorimmunologie en langetermijngevolgen kankerbehandeling 7 december 2010 - Prof.dr.ir. Floor van Leeuwen (NKI-AVL), prof.dr. Kees Melief (LUMC) en prof.dr Carl Figdor (UMC St. Radboud) ont...
Dr. Wolfgang Berthold joins Supervisory Board Merus
September 20, 2010
Utrecht, the Netherlands (September 20, 2010) - Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. "We are delighted to appoint Wolf Ber...
InteRNA Technologies announces establishment of Scientific Advisory Board
July 08, 2010
Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of it...
Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP® for phase III clinical trials
June 02, 2010
Bubendorf, Switzerland and Leiden, Netherlands, Bachem (SIX: BANB) and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of...
Merus Announces Publication of the Generation of Single, Clonal Cell lines
June 02, 2010
Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the 'Early View' section of the journal Biotechnology and Bioengineering that demonstrate for the first time...
Syntarga Announces Additional Antibody-Drug Conjugate Collaborations
May 31, 2010
Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements c...
Syntarga Announces Two Antibody-Drug Conjugate Collaborations with Top-tier Biopharmaceutical Companies
March 03, 2010
Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These latest agreements, adding t...
Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund
January 29, 2010
Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fu...